BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 33158067)

  • 1. Poziotinib Inhibits the Efflux Activity of the ABCB1 and ABCG2 Transporters and the Expression of the ABCG2 Transporter Protein in Multidrug Resistant Colon Cancer Cells.
    Zhang Y; Wu ZX; Yang Y; Wang JQ; Li J; Sun Z; Teng QX; Ashby CR; Yang DH
    Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33158067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
    Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
    Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The AKT inhibitor, MK-2206, attenuates ABCG2-mediated drug resistance in lung and colon cancer cells.
    Gao HL; Cui Q; Wang JQ; Ashby CR; Chen Y; Shen ZX; Chen ZS
    Front Pharmacol; 2023; 14():1235285. PubMed ID: 37521473
    [No Abstract]   [Full Text] [Related]  

  • 4. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
    Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
    Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Novel Benzamide Derivative, VKNG-2, Restores the Efficacy of Chemotherapeutic Drugs in Colon Cancer Cell Lines by Inhibiting the ABCG2 Transporter.
    Narayanan S; Gujarati NA; Wang JQ; Wu ZX; Koya J; Cui Q; Korlipara VL; Ashby CR; Chen ZS
    Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33671108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells.
    Gupta P; Zhang YK; Zhang XY; Wang YJ; Lu KW; Hall T; Peng R; Yang DH; Xie N; Chen ZS
    Cell Physiol Biochem; 2018; 45(4):1515-1528. PubMed ID: 29486476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VS-4718 Antagonizes Multidrug Resistance in ABCB1- and ABCG2-Overexpressing Cancer Cells by Inhibiting the Efflux Function of ABC Transporters.
    Ji N; Yang Y; Cai CY; Lei ZN; Wang JQ; Gupta P; Teng QX; Chen ZS; Kong D; Yang DH
    Front Pharmacol; 2018; 9():1236. PubMed ID: 30425643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lazertinib improves the efficacy of chemotherapeutic drugs in ABCB1 or ABCG2 overexpression cancer cells i
    Fan Y; Tao T; Guo Z; Wah To KK; Chen D; Wu S; Yang C; Li J; Luo M; Wang F; Fu L
    Mol Ther Oncolytics; 2022 Mar; 24():636-649. PubMed ID: 35284628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bafetinib (INNO-406) reverses multidrug resistance by inhibiting the efflux function of ABCB1 and ABCG2 transporters.
    Zhang YK; Zhang GN; Wang YJ; Patel BA; Talele TT; Yang DH; Chen ZS
    Sci Rep; 2016 May; 6():25694. PubMed ID: 27157787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ABCB1 and ABCG2 restricts the efficacy of gedatolisib (PF-05212384), a PI3K inhibitor in colorectal cancer cells.
    Liu C; Xing W; Yu H; Zhang W; Si T
    Cancer Cell Int; 2021 Feb; 21(1):108. PubMed ID: 33593355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Novel Synthetic Dihydroindeno[1,2-b] Indole Derivative (LS-2-3j) Reverses ABCB1- and ABCG2-Mediated Multidrug Resistance in Cancer Cells.
    Guo C; Liu F; Qi J; Ma J; Lin S; Zhang C; Zhang Q; Zhang H; Lu R; Li X
    Molecules; 2018 Dec; 23(12):. PubMed ID: 30544754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Derivative of 5-cyano-6-phenylpyrimidin antagonizes ABCB1- and ABCG2-mediated multidrug resistance.
    Wang JQ; Wang B; Lei ZN; Teng QX; Li JY; Zhang W; Ji N; Cai CY; Ma LY; Liu HM; Chen ZS
    Eur J Pharmacol; 2019 Nov; 863():172611. PubMed ID: 31476282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
    Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olmutinib (BI1482694/HM61713), a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses ABCG2-Mediated Multidrug Resistance in Cancer Cells.
    Zhang W; Fan YF; Cai CY; Wang JQ; Teng QX; Lei ZN; Zeng L; Gupta P; Chen ZS
    Front Pharmacol; 2018; 9():1097. PubMed ID: 30356705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
    Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
    Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
    Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
    Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.
    Ji N; Yang Y; Lei ZN; Cai CY; Wang JQ; Gupta P; Xian X; Yang DH; Kong D; Chen ZS
    Biochem Pharmacol; 2018 Dec; 158():274-285. PubMed ID: 30431011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of Cancer Multidrug Resistance (MDR) Mediated by ATP-Binding Cassette Transporter G2 (ABCG2) by AZ-628, a RAF Kinase Inhibitor.
    Wang JQ; Teng QX; Lei ZN; Ji N; Cui Q; Fu H; Lin L; Yang DH; Fan YF; Chen ZS
    Front Cell Dev Biol; 2020; 8():601400. PubMed ID: 33364237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of abemaciclib (LY2835219) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
    Wu T; Chen Z; To KKW; Fang X; Wang F; Cheng B; Fu L
    Biochem Pharmacol; 2017 Jan; 124():29-42. PubMed ID: 27816545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishment and Characterization of an Irinotecan-Resistant Human Colon Cancer Cell Line.
    Wu ZX; Yang Y; Zeng L; Patel H; Bo L; Lin L; Chen ZS
    Front Oncol; 2020; 10():624954. PubMed ID: 33692943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.